Skip to main content

Advertisement

SpringerLink
Log in

Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review

  • Systematic Review
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective

The objective of this article was to summarize the findings of all the available studies on alternative pharmacological treatments for asthma and assess their methodological quality, as well as to identify the main drivers of the cost effectiveness of pharmacological treatments for the disease.

Methods

A systematic review of the literature in seven electronic databases was conducted in order to identify all the available health economic evidence on alternative pharmacological treatments for asthma published up to April 2017. The reporting quality of the included studies was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement.

Results

A total of 72 studies were included in the review, classified as follows: medications for acute asthma treatment (n = 5, 6.9%); inhaled corticosteroids (ICS) administered alone or in conjunction with long-acting β-agonists (LABA) or tiotropium for chronic asthma treatment (n = 38, 52.8%); direct comparisons between different combinations of ICS, ICS/LABA, leukotriene receptor antagonists (LTRA), and sodium cromoglycate for chronic asthma treatment (n = 14, 19.4%); and omalizumab for chronic asthma treatment (n = 15, 20.8%). ICS were reported to be cost effective when compared with LTRA for the management of persistent asthma. In patients with inadequately controlled asthma taking ICS, the addition of long-acting β-agonist (LABA) preparations has been demonstrated to be cost effective, especially when combinations of ICS/LABA containing formoterol are used for both maintenance and reliever therapy. In patients with uncontrolled severe persistent allergic asthma, omalizumab therapy could be cost effective in a carefully selected subgroup of patients with the more severe forms of the disease. The quality of reporting in the studies, according to the CHEERS checklist, was very uneven. The main cost-effectiveness drivers identified were the cost or rate of asthma exacerbations, the cost or rate of the use of asthma medications, the asthma mortality risk, and the rate of utilization of health services for asthma.

Conclusions

The present findings are in line with the pharmacological recommendations for stepwise management of asthma given in the most recent evidence-based clinical practice guidelines for the disease. The identified reporting quality of the available health economic evidence is useful for identifying aspects where there is room for improvement in future asthma cost-effectiveness studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S7–10.

    Article  PubMed  Google Scholar 

  2. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2016;20(1):11–23.

    Article  CAS  PubMed  Google Scholar 

  4. Castro-Rodriguez JA, Rodrigo GJ, Rodriguez-Martinez CE. Principal findings of systematic reviews of acute asthma treatment in childhood. J Asthma. 2015;52(10):1038–45.

    Article  CAS  PubMed  Google Scholar 

  5. Castro-Rodriguez JA, Rodrigo GJ, Rodriguez-Martinez CE. Principal findings of systematic reviews for chronic treatment in childhood asthma. J Asthma. 2015;52(4):407–16.

    Article  PubMed  Google Scholar 

  6. Lee TA, Weiss KB. An update on the health economics of asthma and allergy. Curr Opin Allergy Clin Immunol. 2002;2(3):195–200.

    Article  PubMed  Google Scholar 

  7. Bahadori K, Quon BS, Doyle-Waters MM, Marra C, Fitzgerald JM. A systematic review of economic evaluations of therapy in asthma. J Asthma Allergy. 2010;3:33–42.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Drummond MF, Sculpher MJ, Torrance GW, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2006.

    Google Scholar 

  9. Campbell JD, Spackman DE, Sullivan SD. Health economics of asthma: assessing the value of asthma interventions. Allergy. 2008;63(12):1581–92.

    Article  CAS  PubMed  Google Scholar 

  10. Cheng JW, Arnold RJ. Pharmacoeconomic review of medical management of persistent asthma. Allergy Asthma Proc. 2008;29(2):109–22.

    Article  CAS  PubMed  Google Scholar 

  11. Dominguez-Ortega J, Phillips-Angles E, Barranco P, Quirce S. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma. 2015;52(6):529–37.

    Article  PubMed  Google Scholar 

  12. Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health technology assessment. 2008;12(19):iii–iv, 1–360.

  13. Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM. Asthma cost-effectiveness analyses: are we using the recommended outcomes in estimating value? J Allergy Clin Immunol Pract. 2018;6(2):619–32.

    Article  PubMed  Google Scholar 

  14. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Pharmacoeconomics. 2013;31(5):361–7.

    Article  PubMed  Google Scholar 

  15. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med. 1995;123(1):61–70.

    Article  Google Scholar 

  16. Davis JC, Robertson MC, Comans T, Scuffham PA. Guidelines for conducting and reporting economic evaluation of fall prevention strategies. Osteoporos Int. 2011;22(9):2449–59.

    Article  CAS  PubMed  Google Scholar 

  17. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care. 2005;21(2):165–71.

    PubMed  Google Scholar 

  18. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313(7052):275–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nuijten MJ, Pronk MH, Brorens MJ, Hekster YA, Lockefeer JH, de Smet PA, et al. Reporting format for economic evaluation. Part II: focus on modelling studies. PharmacoEconomics. 1998;14(3):259–68.

    Article  CAS  PubMed  Google Scholar 

  20. Petrou S, Gray A. Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ. 2011;342:d1766.

    Article  PubMed  Google Scholar 

  21. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005;8(5):521–33.

    Article  PubMed  Google Scholar 

  22. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339–41.

    Article  CAS  PubMed  Google Scholar 

  23. Vintzileos AM, Beazoglou T. Design, execution, interpretation, and reporting of economic evaluation studies in obstetrics. Am J Obstet Gynecol. 2004;191(4):1070–6.

    Article  PubMed  Google Scholar 

  24. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7(2):e1000217.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Andrews AL, Wong KA, Heine D, Scott Russell W. A cost-effectiveness analysis of dexamethasone versus prednisone in pediatric acute asthma exacerbations. Acad Emerg Med. 2012;19(8):943–8.

    Article  PubMed  Google Scholar 

  26. Powell CV, Kolamunnage-Dona R, Lowe J, Boland A, Petrou S, Doull I, et al. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo-controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children. Health Technol Assess. 2013;17(45):v–vi, 1–216.

  27. Rodrigo GJ, Rodrigo C. Cost effectiveness of the application of inhaled ipratropium bromide in the treatment of adult patients with acute asthma in Uruguay [in Spanish]. Rev Alerg Mex. 2003;50(3):103–7.

    PubMed  Google Scholar 

  28. Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005;23(7):842–7.

  29. Thomas K, Peter JV, Cherian AM, Guyatt G. Cost-effectiveness of inhaled beta-agonists v. oral salbutamol in asthma: a randomized double-blind cross-over study. Natl Med J India. 1996;9(4):159–62.

    CAS  PubMed  Google Scholar 

  30. Andersson F, Stahl E, Barnes PJ, Lofdahl CG, O’Byrne PM, Pauwels RA, et al. Adding formoterol to budesonide in moderate asthma–health economic results from the FACET study. Respir Med. 2001;95(6):505–12.

    Article  CAS  PubMed  Google Scholar 

  31. Barnes NC, Thwaites RM, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med. 1999;93(6):402–7.

    Article  CAS  PubMed  Google Scholar 

  32. Bisgaard H, Price MJ, Maden C, Olsen NA. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus babyhaler spacer in the treatment of asthma in preschool-aged children. Chest. 2001;120(6):1835–42.

    Article  CAS  PubMed  Google Scholar 

  33. Bruggenjurgen B, Ezzat N, Kardos P, Buhl R. Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment. Allergy. 2010;65(9):1108–15.

    CAS  PubMed  Google Scholar 

  34. Bruggenjurgen B, Selim D, Kardos P, Richter K, Vogelmeier C, Roll S, et al. Economic assessment of adjustable maintenance treatment with budesonide/formoterol in a single inhaler versus fixed treatment in asthma. Pharmacoeconomics. 2005;23(7):723–31.

    Article  PubMed  Google Scholar 

  35. Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, et al. Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma. Curr Med Res Opin. 2007;23(5):1147–59.

    Article  CAS  PubMed  Google Scholar 

  36. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respir Med. 2006;100(4):586–94.

    Article  CAS  PubMed  Google Scholar 

  37. Everden P, Lloyd A, Hutchinson J, Plumb J. Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. Respir Med. 2002;96(4):250–8.

    Article  CAS  PubMed  Google Scholar 

  38. Gerzeli S, Rognoni C, Quaglini S, Cavallo MC, Cremonesi G, Papi A. Cost-effectiveness and cost-utility of beclomethasone/formoterol versus fluticasone propionate/salmeterol in patients with moderate to severe asthma. Clin Drug Investig. 2012;32(4):253–65.

    Article  PubMed  Google Scholar 

  39. Goossens LM, Riemersma RA, Postma DS, van der Molen T, Rutten-van Molken MP. An economic evaluation of budesonide/formoterol for maintenance and reliever treatment in asthma in general practice. Adv Ther. 2009;26(9):872–85.

    Article  PubMed  Google Scholar 

  40. Ismaila AS, Risebrough N, Li C, Corriveau D, Hawkins N, FitzGerald JM, et al. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada. Respir Med. 2014;108(9):1292–302.

    Article  PubMed  Google Scholar 

  41. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics. 2006;24(7):695–708.

    Article  CAS  PubMed  Google Scholar 

  42. Lundback B, Jenkins C, Price MJ, Thwaites RM. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 microg twice daily and budesonide 800 microg twice daily in the treatment of adults and adolescents with asthma. International Study Group. Respir Med. 2000;94(7):724–32.

    Article  CAS  PubMed  Google Scholar 

  43. Lundborg M, Wille S, Bjermer L, Tilling B, Lundgren M, Telg G, et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin. 2006;22(5):809–21.

    Article  CAS  PubMed  Google Scholar 

  44. Malone DC, Luskin AT. Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. Respir Med. 2003;97(12):1269–76.

    Article  CAS  PubMed  Google Scholar 

  45. Miller E, FitzGerald JM. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies—a Canadian economic evaluation. Can J Clin Pharmacol. 2008;15(2):e165–76.

    PubMed  Google Scholar 

  46. Miller E, Sears MR, McIvor A, Liovas A. Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma. Can Respir J. 2007;14(5):269–75.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Miyagawa T, Arakawa I, Shiragami M, Nishimura S. Cost-effectiveness of including salmeterol in asthma therapy in a primary care setting in Japan. Yakugaku Zasshi. 2006;126(1):51–9.

    Article  CAS  PubMed  Google Scholar 

  48. Paggiaro P, Patel S, Nicolini G, Pradelli L, Zaniolo O, Papi A. Stepping down from high dose fluticasone/salmeterol to extrafine BDP/F in asthma is cost-effective. Respir Med. 2013;107(10):1531–7.

    Article  PubMed  Google Scholar 

  49. Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics. 2002;20(10):653–64.

    Article  CAS  PubMed  Google Scholar 

  50. Price D, Haughney J, Lloyd A, Hutchinson J, Plumb J. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study. Curr Med Res Opin. 2004;20(10):1671–9.

    Article  PubMed  Google Scholar 

  51. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy. 2007;62(10):1189–98.

    Article  CAS  PubMed  Google Scholar 

  52. Price DB, Cargill K, Wolfe S, Darby H. Salmeterol xinafoate: an analysis of outcomes and cost-effectiveness using a primary care database. Respir Med. 1998;92(11):1302–4.

    Article  CAS  PubMed  Google Scholar 

  53. Rodriguez-Martinez CE, Sossa-Briceno MP, Castro-Rodriguez JA. Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma. J Asthma. 2013;50(4):410–8.

    Article  PubMed  Google Scholar 

  54. Rutten-van Molken MP, van Doorslaer EK, Till MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics. 1998;14(6):671–84.

    Article  CAS  PubMed  Google Scholar 

  55. Stallberg B, Ekstrom T, Neij F, Olsson P, Skoogh BE, Wennergren G, et al. A real-life cost-effectiveness evaluation of budesonide/formoterol maintenance and reliever therapy in asthma. Respir Med. 2008;102(10):1360–70.

    Article  CAS  PubMed  Google Scholar 

  56. Stempel DA, Stanford RH, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin Ther. 2000;22(12):1562–74.

    Article  CAS  PubMed  Google Scholar 

  57. Volmer T, Kielhorn A, Weber HH, Wiessmann KJ. Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma. Pharmacoeconomics. 1999;16(5 Pt 2):525–31.

    Article  CAS  PubMed  Google Scholar 

  58. Weiss K, Buxton M, Andersson FL, Lamm CJ, Liljas B, Sullivan SD. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study. Pediatr Allergy Immunol. 2006;17(Suppl 17):21–7.

    Article  PubMed  Google Scholar 

  59. Wickstrom J, Dam N, Malmberg I, Hansen BB, Lange P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy in Denmark: cost-effectiveness analysis based on five randomised controlled trials. Clin Respir J. 2009;3(3):169–80.

    Article  PubMed  CAS  Google Scholar 

  60. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol. 2001;108(1):39–46.

    Article  CAS  PubMed  Google Scholar 

  61. Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country: an epilogue. Arch Dis Child. 1995;73(5):482.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol. 2003;112(6):1229–36.

    Article  PubMed  Google Scholar 

  63. Palmqvist M, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 μg vs fluticasone propionate 250 μg in adults and adolescents with asthma IV: results. Pharmacoeconomics. 1999;16(Suppl 2):23.

    Article  CAS  Google Scholar 

  64. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 μg vs fluticasone propionate 100 μg in adults and adolescents with asthma III: results. Pharmacoeconomics. 1999;16(Suppl 2):15.

    Article  CAS  Google Scholar 

  65. Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F, et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J. 2013;22(4):439–48.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Stanciole AE, Ortegon M, Chisholm D, Lauer JA. Cost effectiveness of strategies to combat chronic obstructive pulmonary disease and asthma in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344:e608.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Willson J, Bateman ED, Pavord I, Lloyd A, Krivasi T, Esser D. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting beta-agonists. Appl Health Econ Health Policy. 2014;12(4):447–59.

    Article  PubMed  Google Scholar 

  68. Andersson F, Kjellman M, Forsberg G, Moller C, Arheden L. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. Ann Allergy Asthma Immunol. 2001;86(5):537–44.

    Article  CAS  PubMed  Google Scholar 

  69. Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves. Ann Allergy Asthma Immunol. 2005;95(2):181–9.

    Article  PubMed  Google Scholar 

  70. Heaton PC, Guo JJ, Hornung RW, Johnston JA, Jang R, Moomaw CJ, et al. Analysis of the effectiveness and cost benefit of leukotriene modifiers in adults with asthma in the Ohio Medicaid population. J Manag Care Pharm. 2006;12(1):33–42.

    PubMed  Google Scholar 

  71. Menendez R, Stanford RH, Edwards L, Kalberg C, Rickard K. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma. Pharmacoeconomics. 2001;19(8):865–74.

    Article  CAS  PubMed  Google Scholar 

  72. O’Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics. 2004;22(12):815–25.

    Article  PubMed  Google Scholar 

  73. O’Connor RD, O’Donnell JC, Pinto LA, Wiener DJ, Legorreta AP. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest. 2002;121(4):1028–35.

    Article  PubMed  Google Scholar 

  74. Price D, Musgrave S, Wilson E, Sims E, Shepstone L, Blyth A, et al. A pragmatic single-blind randomised controlled trial and economic evaluation of the use of leukotriene receptor antagonists in primary care at steps 2 and 3 of the national asthma guidelines (ELEVATE study). Health Technol Assess. 2011;15(21):1–132.

    Article  CAS  PubMed  Google Scholar 

  75. Rely K, McQuire SE, Alexandre PK, Escudero GS. Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children [in Spanish]. Value Health. 2011;14(5 Suppl 1):S43–7.

    Article  PubMed  Google Scholar 

  76. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics. 2002;20(13):909–18.

    Article  PubMed  Google Scholar 

  77. Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007;25(7):577–90.

    Article  PubMed  Google Scholar 

  78. Stempel DA, Kruzikas DT, Manjunath R. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast. J Pediatr. 2007;150(2):162–7.

    Article  CAS  PubMed  Google Scholar 

  79. Tan H, Sarawate C, Singer J, Elward K, Cohen RI, Smart BA, et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc. 2009;84(8):675–84.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, et al. Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2011;127(1):161–6, 6.e1.

  81. Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, et al. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial. Pharmacoeconomics. 2010;28(7):597–608.

    Article  PubMed  Google Scholar 

  82. Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J, et al. Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial. Pharmacoeconomics. 2010;28(7):585–95.

    Article  PubMed  Google Scholar 

  83. Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy. 2007;62(2):149–53.

    Article  CAS  PubMed  Google Scholar 

  84. Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy. 2010;65(9):1141–8.

    CAS  PubMed  Google Scholar 

  85. Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843–8.

    Article  CAS  Google Scholar 

  86. Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health. 2014;17(8):772–82.

    Article  PubMed  Google Scholar 

  87. Levy AN, Garcia ARAJ, Garcia-Agua Soler N, Sanjuan MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205–10.

    Article  PubMed  Google Scholar 

  88. Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1–342.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265–9.

    Article  PubMed  Google Scholar 

  90. van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342–8.

    Article  PubMed  Google Scholar 

  91. Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567–78.

    Article  PubMed  Google Scholar 

  92. Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120(5):1146–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Yoshikawa H, Iwata M, Matsuzaki H, Ono R, Murakami Y, Taba N, et al. Impact of omalizumab on medical cost of childhood asthma in Japan. Pediatr Int. 2016;58(5):425–8.

    Article  PubMed  Google Scholar 

  94. Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29–36.

    Article  PubMed  Google Scholar 

  95. Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45–53.

    Google Scholar 

  96. Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765–76.

    Article  CAS  PubMed  Google Scholar 

  97. Zafari Z, Sadatsafavi M, Marra CA, Chen W, FitzGerald JM. Cost-effectiveness of bronchial thermoplasty, omalizumab, and standard therapy for moderate-to-severe allergic asthma. PLoS One. 2016;11(1):e0146003.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. Perera BJ. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country. Archives of disease in childhood. 1995;72(4):312–5 (discussion 5–6).

  99. Price DB, Appleby JL. Fluticasone propionate: an audit of outcomes and cost-effectiveness in primary care. Respir Med. 1998;92(2):351–3.

    Article  CAS  PubMed  Google Scholar 

  100. Stempel DA. Economic analysis of asthma practices. American journal of managed care. 2000;6(17 Suppl):S930–6; (discussion S7–9).

  101. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics. 2002;20(3):183–94.

    Article  PubMed  Google Scholar 

  102. Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma: a national clinical guideline. Edinburgh: SIGN; 2016.

  103. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2017. http://www.ginasthma.org. Accessed 9 Jan 2018

  104. Tadrous M, Khuu W, Lebovic G, Stanbrook MB, Martins D, Paterson JM, et al. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann Allergy Asthma Immunol. 2018;120(1):59–65.e2.

  105. Beca J, Chan KK. Cost-effectiveness of pazopanib: an example of improved transparency and accessibility of industry-sponsored economic evaluations through publication in peer-reviewed journals. Curr Oncol. 2016;23(4):e327–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.

    Article  PubMed  Google Scholar 

  107. Ten Jonsson B. arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9.

    Article  Google Scholar 

  108. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479–500.

    Article  CAS  PubMed  Google Scholar 

  109. Kim DD, Wilkinson CL, Pope EF, Chambers JD, Cohen JT, Neumann PJ. The influence of time horizon on results of cost-effectiveness analyses. Exp Rev Pharmacoecon Outcomes Res. 2017;17(6):615–23.

    Article  Google Scholar 

  110. Wisniewski JA, McLaughlin AP, Stenger PJ, Patrie J, Brown MA, El-Dahr JM, et al. A comparison of seasonal trends in asthma exacerbations among children from geographic regions with different climates. Allergy Asthma Proc. 2016;37(6):475–81.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6(1):9–17.

    Article  PubMed  Google Scholar 

  112. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol. 2008;52(25):2119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol. 2012;129(3 Suppl):S49–64.

    Article  PubMed  PubMed Central  Google Scholar 

  114. Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? J Asthma. 2017;54(1):17–23.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Mr. Charlie Barret for his editorial assistance.

Author information

Authors and Affiliations

  1. Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Carrera 45 No. 26–85, Bogota, Colombia

    Carlos E. Rodriguez-Martinez

  2. Department of Pediatric Pulmonology and Pediatric Critical Care Medicine, School of Medicine, Universidad El Bosque, Av. Cra 9 No. 131A–02, Bogota, Colombia

    Carlos E. Rodriguez-Martinez

  3. Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia, Carrera 45 No. 26–85, Bogota, Colombia

    Monica P. Sossa-Briceño

  4. Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Av Libertador Bernardo O’Higgins 340, Santiago, Región Metropolitana, Chile

    Jose A. Castro-Rodriguez

Authors
  1. Carlos E. Rodriguez-Martinez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Monica P. Sossa-Briceño
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jose A. Castro-Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. RM conceptualized and designed the study, carried out the initial analyses, drafted the initial manuscript, and approved the final version as submitted. Dr. SB critically reviewed and revised the manuscript, and approved the final version as submitted. Dr. CR carried out the initial analyses, reviewed and revised the manuscript, and approved the final version as submitted. All authors approved the final version of the manuscript as submitted and agree to be accountable for all aspects of the work.

Corresponding author

Correspondence to Carlos E. Rodriguez-Martinez.

Ethics declarations

Conflicts of interest

Carlos E. Rodriguez-Martinez, Monica P. Sossa-Briceno, and Jose A. Castro-Rodriguez declare that they have no conflicts of interest.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rodriguez-Martinez, C.E., Sossa-Briceño, M.P. & Castro-Rodriguez, J.A. Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review. PharmacoEconomics 36, 1165–1200 (2018). https://doi.org/10.1007/s40273-018-0668-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-018-0668-8

Search

Navigation